Skip to content

Study · Randomized controlled trial · n = 10 · 2016

14 results

Pegvisomant-primed glucagon stimulation test in assessing GH reserve and GH/IGF kinetics in adults suspected of GH deficiency.

Yuen KC, Frystyk J, Rhoads SA, Bidlingmaier M

Pituitary1 Feb 2016Cited by 1 (Europe PMC)

PMID26496767 (opens in a new tab)DOI10.1007/s11102-015-0688-8 (opens in a new tab)PepBankPUB-26496767
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In adults with suspected GH deficiency, basal GH with pegvisomant-primed glucagon testing was comparable to that with glucagon testing and insulin tolerance testing.

    In plain wordsIn adults with suspected GH deficiency, basal GH during the pegvisomant-primed glucagon test was comparable to the glucagon and insulin tolerance tests.

    Peptide
    Pegvisomant
    Outcome
    Direction not reportedBasal GH during diagnostic testing
    Study

    n = 10

    Comparator
    Glucagon stimulation test and insulin tolerance test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Basal and peak GH levels with the PegV-GST were comparable to those of the GST and ITT.
    2 context sentences
    Summary · context
    Adults suspected of GHD underwent PegVGST,GST and insulin tolerance test (ITT) in random order.Growth hormone levels (measured by a PegV insensitive assay) during PegV-GST, GST and ITT were compared,and acute effects of PegV on GH/IGF kinetics were assessed.
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  2. 02HumanRandomized controlled trialActivity measurement

    In adults with suspected GH deficiency, peak GH with pegvisomant-primed glucagon testing was comparable to that with glucagon testing and insulin tolerance testing.

    In plain wordsIn adults with suspected GH deficiency, peak GH during the pegvisomant-primed glucagon test was comparable to the glucagon and insulin tolerance tests.

    Peptide
    Pegvisomant
    Outcome
    Direction not reportedPeak GH during diagnostic testing
    Study

    n = 10

    Comparator
    Glucagon stimulation test and insulin tolerance test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Basal and peak GH levels with the PegV-GST were comparable to those of the GST and ITT.
    2 context sentences
    Summary · context
    Adults suspected of GHD underwent PegVGST,GST and insulin tolerance test (ITT) in random order.Growth hormone levels (measured by a PegV insensitive assay) during PegV-GST, GST and ITT were compared,and acute effects of PegV on GH/IGF kinetics were assessed.
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  3. 03HumanRandomized controlled trialActivity measurement

    In adults with suspected GH deficiency, the same five subjects who failed the glucagon stimulation test and insulin tolerance test failed the pegvisomant-primed glucagon test, using a peak GH cut point of <3 ng/mL for the primed test.

    In plain wordsIn adults with suspected GH deficiency, the five people who failed the glucagon and insulin tolerance tests also failed the pegvisomant-primed glucagon test.

    Peptide
    Pegvisomant
    Outcome
    Not applicableDiagnostic failure concordance
    Study

    n = 10

    Comparator
    Glucagon stimulation test and insulin tolerance test
    Outcome group
    Diagnostic test performance · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Subjects failing GST, ITT and PegV-GST
    5 subjects
    adults suspected of GH deficiency
    Peak GH cut point for PegV-GST
    < 3 ng/mL
    PegV-GST failure threshold

    Source sentences

    Summary
    The five subjects that failed the GST and ITT were the same subjects that failed the PegVGST,using the peak GH cut point of<3 ng/mL for this test.
    2 context sentences
    Summary · context
    Adults suspected of GHD underwent PegVGST,GST and insulin tolerance test (ITT) in random order.Growth hormone levels (measured by a PegV insensitive assay) during PegV-GST, GST and ITT were compared,and acute effects of PegV on GH/IGF kinetics were assessed.
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with suspected GH deficiency, basal GH increased after pegvisomant priming (P<0.01).

    In plain wordsIn adults with suspected GH deficiency, pegvisomant increased basal GH compared with before priming.

    Peptide
    Pegvisomant
    Outcome
    IncreaseBasal GH
    Study

    n = 10

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After PegV priming, basal GH and GH binding protein(GHBP) increased (both P<0.01) and total IGF-I and bioactive IGF decreased (both P<0.05), whereas IGF-II and IGFBPs -1, -2 and -3 were unchanged compared to pre-PegV priming.
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with suspected GH deficiency, GH binding protein increased after pegvisomant priming (P<0.01).

    In plain wordsIn adults with suspected GH deficiency, pegvisomant increased GH binding protein compared with before priming.

    Peptide
    Pegvisomant
    Outcome
    IncreaseGH binding protein
    Study

    n = 10

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After PegV priming, basal GH and GH binding protein(GHBP) increased (both P<0.01) and total IGF-I and bioactive IGF decreased (both P<0.05), whereas IGF-II and IGFBPs -1, -2 and -3 were unchanged compared to pre-PegV priming.
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  6. 06HumanNon-randomized trialEfficacy outcome

    In adults with suspected GH deficiency, total IGF-I decreased after pegvisomant priming (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, pegvisomant reduced total IGF-I compared with before priming.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTotal IGF-I
    Study

    n = 10

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After PegV priming, basal GH and GH binding protein(GHBP) increased (both P<0.01) and total IGF-I and bioactive IGF decreased (both P<0.05), whereas IGF-II and IGFBPs -1, -2 and -3 were unchanged compared to pre-PegV priming.
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  7. 07HumanNon-randomized trialEfficacy outcome

    In adults with suspected GH deficiency, bioactive IGF decreased after pegvisomant priming (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, pegvisomant reduced bioactive IGF compared with before priming.

    Peptide
    Pegvisomant
    Outcome
    DecreaseBioactive IGF
    Study

    n = 10

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After PegV priming, basal GH and GH binding protein(GHBP) increased (both P<0.01) and total IGF-I and bioactive IGF decreased (both P<0.05), whereas IGF-II and IGFBPs -1, -2 and -3 were unchanged compared to pre-PegV priming.
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  8. 08HumanNon-randomized trialEfficacy outcome

    In adults with suspected GH deficiency, IGF-II and IGFBPs -1, -2 and -3 were unchanged after pegvisomant priming.

    In plain wordsIn adults with suspected GH deficiency, IGF-II and listed binding proteins were unchanged compared with before pegvisomant priming.

    Peptide
    Pegvisomant
    Outcome
    No significant changeIGF-II and IGFBPs -1, -2 and -3
    Study

    n = 10

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After PegV priming, basal GH and GH binding protein(GHBP) increased (both P<0.01) and total IGF-I and bioactive IGF decreased (both P<0.05), whereas IGF-II and IGFBPs -1, -2 and -3 were unchanged compared to pre-PegV priming.
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  9. 09HumanObservational studyPharmacokinetics

    In adults with suspected GH deficiency, serum pegvisomant was positively correlated with basal GH (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, higher serum pegvisomant was linked to higher basal GH.

    Peptide
    Pegvisomant
    Outcome
    IncreaseExposure correlation with basal GH
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum PegV levels correlated positively with basal GH, peak GH, IGFBP-1 and IGFBP-2 levels, and negatively with D bioactive IGF and DGHBP (all P<0.05).
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  10. 10HumanObservational studyPharmacokinetics

    In adults with suspected GH deficiency, serum pegvisomant was positively correlated with peak GH (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, higher serum pegvisomant was linked to higher peak GH.

    Peptide
    Pegvisomant
    Outcome
    IncreaseExposure correlation with peak GH
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum PegV levels correlated positively with basal GH, peak GH, IGFBP-1 and IGFBP-2 levels, and negatively with D bioactive IGF and DGHBP (all P<0.05).
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  11. 11HumanObservational studyPharmacokinetics

    In adults with suspected GH deficiency, serum pegvisomant was positively correlated with IGFBP-1 (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, higher serum pegvisomant was linked to higher IGFBP-1.

    Peptide
    Pegvisomant
    Outcome
    IncreaseExposure correlation with IGFBP-1
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum PegV levels correlated positively with basal GH, peak GH, IGFBP-1 and IGFBP-2 levels, and negatively with D bioactive IGF and DGHBP (all P<0.05).
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  12. 12HumanObservational studyPharmacokinetics

    In adults with suspected GH deficiency, serum pegvisomant was positively correlated with IGFBP-2 (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, higher serum pegvisomant was linked to higher IGFBP-2.

    Peptide
    Pegvisomant
    Outcome
    IncreaseExposure correlation with IGFBP-2
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum PegV levels correlated positively with basal GH, peak GH, IGFBP-1 and IGFBP-2 levels, and negatively with D bioactive IGF and DGHBP (all P<0.05).
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  13. 13HumanObservational studyPharmacokinetics

    In adults with suspected GH deficiency, serum pegvisomant correlated negatively with D bioactive IGF (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, higher serum pegvisomant was linked to lower D bioactive IGF.

    Peptide
    Pegvisomant
    Outcome
    DecreaseExposure correlation with D bioactive IGF
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum PegV levels correlated positively with basal GH, peak GH, IGFBP-1 and IGFBP-2 levels, and negatively with D bioactive IGF and DGHBP (all P<0.05).
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.
  14. 14HumanObservational studyPharmacokinetics

    In adults with suspected GH deficiency, serum pegvisomant correlated negatively with DGHBP (P<0.05).

    In plain wordsIn adults with suspected GH deficiency, higher serum pegvisomant was linked to lower DGHBP.

    Peptide
    Pegvisomant
    Outcome
    DecreaseExposure correlation with DGHBP
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum PegV levels correlated positively with basal GH, peak GH, IGFBP-1 and IGFBP-2 levels, and negatively with D bioactive IGF and DGHBP (all P<0.05).
    1 context sentence
    Summary · context
    Ten subjects with hypothalamic-pituitary disease and 1–4 pituitary hormone deficiencies were studied.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT01804413

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Oregon Health and Science Universityn = 10Mar 2011 to est. Dec 2013

Adults Growth Hormone Deficiency.

Trial pageClinicalTrials.govUpdated 24 Oct 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.